Bristol-Myers Squibb Company

NYSE:BMY Stock Report

Market Cap: US$121.4b

Bristol-Myers Squibb Future Growth

Future criteria checks 4/6

Bristol-Myers Squibb's revenue is forecast to decline at 4.5% per annum while its annual earnings are expected to grow at 31.9% per year. EPS is expected to grow by 30.2% per annum. Return on equity is forecast to be 45.4% in 3 years.

Key information

31.9%

Earnings growth rate

30.2%

EPS growth rate

Pharmaceuticals earnings growth17.1%
Revenue growth rate-4.5%
Future return on equity45.4%
Analyst coverage

Good

Last updated11 Mar 2025

Recent future growth updates

Recent updates

Bristol-Myers Squibb Stock: A Strong Buy Amid Oncology Success

Feb 21

Bristol-Myers Squibb: Solid Q4 Earnings, But Weak Guidance And Patent Concerns Drive The Stock Down

Feb 07

Bristol-Myers Squibb: Too Valuable Not To Hold This Pharma Gem, But Debt Challenges Remain

Jan 31

Bristol-Myers Squibb (NYSE:BMY) Is Increasing Its Dividend To $0.62

Dec 29
Bristol-Myers Squibb (NYSE:BMY) Is Increasing Its Dividend To $0.62

Bristol-Myers Squibb Will Handle The Patent Cliff And Is Still Undervalued

Dec 20

Bristol-Myers Squibb (NYSE:BMY) Is Paying Out A Larger Dividend Than Last Year

Dec 15
Bristol-Myers Squibb (NYSE:BMY) Is Paying Out A Larger Dividend Than Last Year

Revenues Not Telling The Story For Bristol-Myers Squibb Company (NYSE:BMY)

Nov 27
Revenues Not Telling The Story For Bristol-Myers Squibb Company (NYSE:BMY)

5 Reasons Bristol-Myers Squibb Looks Good Now (Rating Upgrade)

Nov 25

Bristol-Myers Squibb Deserves Its Place Among Its Big Pharma Brethren

Oct 28

Bristol-Myers Squibb: A High-Yield Bargain With Growth On The Horizon

Oct 06

Bristol-Myers Squibb: Cobenfy Approval A Major Coup For The Dealmaker (Upgrade)

Sep 27

Bristol-Myers Still A Value Play Despite Appreciating 26.56% From 2024 Lows

Sep 06

Bristol-Myers Squibb Company's (NYSE:BMY) Share Price Is Matching Sentiment Around Its Revenues

Aug 15
Bristol-Myers Squibb Company's (NYSE:BMY) Share Price Is Matching Sentiment Around Its Revenues

Bristol-Myers Squibb: A Potential Comeback In Healthcare

Aug 06

Bristol-Myers Squibb: Q2 Earnings Look Like An Inflection Point

Jul 27

Bristol Myers Squibb: The More It Drops, The More I Buy

Jul 16

Is Bristol-Myers Squibb (NYSE:BMY) A Risky Investment?

Jun 13
Is Bristol-Myers Squibb (NYSE:BMY) A Risky Investment?

Bristol Myers: Quality Fundamentals Suppressed By Interest Rates

Jun 09

Bristol-Myers Squibb: Looking Beyond The One-Time Quarterly Loss

Jun 03

Bristol-Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be A Generational Buying Opportunity

May 23

Earnings and Revenue Growth Forecasts

NYSE:BMY - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202742,9729,64414,00912,55420
12/31/202643,1029,83613,62612,93023
12/31/202545,73710,49716,10714,00524
12/31/202448,300-8,94813,94215,190N/A
9/30/202447,435-7,25813,80315,003N/A
6/30/202446,509-6,54112,94514,163N/A
3/31/202445,534-6,14812,50913,724N/A
12/31/202345,0068,02512,65113,860N/A
9/30/202344,9358,28511,46812,914N/A
6/30/202345,1877,96310,49911,850N/A
3/31/202345,8487,31110,86012,224N/A
12/31/202246,1596,32711,94813,066N/A
9/30/202246,7386,67712,94613,817N/A
6/30/202247,1446,61714,50215,396N/A
3/31/202246,9606,25115,34716,195N/A
12/31/202146,3856,99415,23416,207N/A
9/30/202145,468-5,40514,56915,505N/A
6/30/202144,384-5,07911,68712,506N/A
3/31/202142,810-6,21913,21513,939N/A
12/31/202042,518-9,01513,29914,052N/A
9/30/202039,395-4412,15712,878N/A
6/30/202034,862-56312,40913,167N/A
3/31/202031,0069549,93910,757N/A
12/31/201926,1453,4397,3748,210N/A
9/30/201924,1735,6557,5838,458N/A
6/30/201923,8576,2036,2727,181N/A
3/31/201923,2885,1445,2396,155N/A
12/31/201822,5614,9206,1157,066N/A
9/30/201822,0371,432N/A4,628N/A
6/30/201821,600376N/A5,062N/A
3/31/201821,040919N/A5,589N/A
12/31/201720,7761,007N/A5,275N/A
9/30/201720,5704,229N/A5,601N/A
6/30/201720,2384,586N/A5,292N/A
3/31/201719,9654,836N/A4,147N/A
12/31/201619,4274,457N/A3,058N/A
9/30/201618,4713,366N/A2,226N/A
6/30/201617,6182,870N/A1,346N/A
3/31/201616,9101,574N/A978N/A
12/31/201516,5601,565N/A2,105N/A
9/30/201516,5311,775N/A1,793N/A
6/30/201516,3831,790N/A2,172N/A
3/31/201516,1092,253N/A3,157N/A
12/31/201415,8792,004N/A3,148N/A
9/30/201416,0622,717N/A3,986N/A
6/30/201416,2062,688N/A4,136N/A
3/31/201416,3652,891N/A4,590N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: BMY is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.8%).

Earnings vs Market: BMY is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: BMY is expected to become profitable in the next 3 years.

Revenue vs Market: BMY's revenue is expected to decline over the next 3 years (-4.5% per year).

High Growth Revenue: BMY's revenue is forecast to decline over the next 3 years (-4.5% per year).

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: BMY's Return on Equity is forecast to be very high in 3 years time (45.4%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/13 10:56
End of Day Share Price 2025/03/13 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Bristol-Myers Squibb Company is covered by 44 analysts. 24 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David ToungArgus Research Company
Ishan MajumdarBaptista Research
Charles ButlerBarclays